NASDAQ:IMCR

Immunocore (IMCR) Stock Forecast, Price & News

$51.88

-0.16 (-0.31%)

(As of 12:20 PM ET)

Compare

Today's Range: $49.54
▼
$51.95
50-Day Range: $49.50
▼
$66.60
52-Week Range: $43.00
▼
$69.06

Volume: 86,372 shs
Average Volume: 243,832 shs
Market Capitalization: $2.54 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $71.38

Immunocore MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.92 Rating Score
Upside/Downside: 38.5% Upside
$71.38 Price Target
Short Interest: Bearish
6.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.40) to ($1.52) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

575th out of 963 stocks

Biological Products, Except Diagnostic Industry

91st out of 160 stocks

4.5

Analyst's Opinion

Consensus Rating
Immunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $71.38, Immunocore has a forecasted upside of 38.5% from its current price of $51.53.
Amount of Analyst Coverage
Immunocore has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
6.24% of the float of Immunocore has been sold short.
Short Interest Ratio / Days to Cover
Immunocore has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Immunocore has recently increased by 4.18%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Immunocore does not currently pay a dividend.
Dividend Growth
Immunocore does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMCR.

3.0

News and Social Media Coverage

News Sentiment
Immunocore has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Immunocore this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for IMCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
2 people have added Immunocore to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunocore insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.70% of the stock of Immunocore is held by insiders.
Percentage Held by Institutions
73.45% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunocore are expected to decrease in the coming year, from ($1.40) to ($1.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunocore is -39.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunocore is -39.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunocore has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Price History

30 days | 90 days | 365 days | Advanced Chart

IMCR Stock News Headlines

September 7, 2023 | marketbeat.com

Institutions are Buying These 3 Stocks and Analysts Agree (IMCR)

Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.

September 23, 2023 | americanbankingnews.com

Immunocore (NASDAQ:IMCR) PT Raised to $85.00 at Oppenheimer

September 25, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

September 22, 2023 | msn.com

Cardlytics, Immunocore See Activist Action

September 22, 2023 | americanbankingnews.com

Immunocore (NASDAQ:IMCR) Trading 2.8% Higher After Analyst Upgrade

September 18, 2023 | americanbankingnews.com

Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Brokerages

September 15, 2023 | americanbankingnews.com

Immunocore (NASDAQ:IMCR) Upgraded at JPMorgan Chase & Co.

September 15, 2023 | americanbankingnews.com

Immunocore (NASDAQ:IMCR) Now Covered by Needham & Company LLC

September 25, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

September 13, 2023 | msn.com

Needham Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Buy Recommendation

September 13, 2023 | markets.businessinsider.com

Analyst Expectations for Immunocore Hldgs's Future

September 13, 2023 | markets.businessinsider.com

Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says

August 23, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Immunocore Holdings (IMCR)

August 16, 2023 | msn.com

Capital One Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Overweight Recommendation

August 13, 2023 | finance.yahoo.com

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Call Transcript

August 11, 2023 | msn.com

Oppenheimer Maintains Immunocore Holdings plc - ADR (IMCR) Outperform Recommendation

August 11, 2023 | msn.com

BTIG Maintains Immunocore Holdings plc - ADR (IMCR) Buy Recommendation

August 10, 2023 | finanznachrichten.de

Immunocore Holdings Limited: Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023 | finance.yahoo.com

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023 | benzinga.com

Immunocore Hldgs's Earnings Outlook

August 8, 2023 | finance.yahoo.com

Why Earnings Season Could Be Great for Immunocore (IMCR)

August 3, 2023 | finance.yahoo.com

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

July 18, 2023 | finance.yahoo.com

Immunocore Holdings (NASDAQ:IMCR) shareholders have earned a 41% return over the last year

July 17, 2023 | msn.com

Canaccord Genuity Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Hold Recommendation

June 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immunocore Holdings (IMCR)

June 26, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Walgreens Boots Alliance (WBA) and Genmab (GMAB)

June 20, 2023 | markets.businessinsider.com

Goldman Sachs Sticks to Its Buy Rating for Immunocore Holdings (IMCR)

See More Headlines

Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Company Calendar

Last Earnings: 8/10/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMCR
CUSIP: N/A
CIK: 1671927
Web: www.immunocore.com
Phone: 44-12-3543-8600
Fax: N/A
Employees: 408
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $71.38
High Stock Price Forecast: $91.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +37.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.92
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,990,000.00
Net Margins: -27.72%
Pretax Margin: -25.99%
Return on Equity: -17.97%
Return on Assets: -11.54%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 4.28
Quick Ratio: 4.26

Sales & Book Value

Annual Sales: $173.59 million
Price / Sales: 14.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.17 per share
Price / Book: 7.26

Miscellaneous

Outstanding Shares: 48,940,000
Free Float: 46,151,000
Market Cap: $2.55 billion
Optionable: Not Optionable
Beta: 0.67

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Bahija Jallal Ph.D. (Age 61)
CEO & Director
Comp: $1.42M

Mr. Brian R. Di Donato M.B.A. (Age 56)
CFO & Head of Strategy

Ms. Annelise Vuidepot Ph.D.
CTO and Head of Pipeline & Platform Research

Clayton Robertson
Head of Investor Relations

Ms. Lily Margaret Hepworth
Gen. Counsel & Company Sec.

Ms. Amy Judge-Prein
Chief Compliance Officer

Mr. Sébastien Desprez
Head of Communications

Ms. Tina St. Leger (Age 55)
Chief HR Officer & Director

Dr. David Berman M.D. (Age 52)
Ph.D., Head of R&D

Ms. Debra Nielsen
Chief of Staff

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IMCR Stock - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings or view top-rated stocks.
What is Immunocore's stock price forecast for 2023?: 13 Wall Street analysts have issued 1-year price targets for Immunocore's stock. Their IMCR share price forecasts range from $16.00 to $91.00. On average, they predict the company's stock price to reach $71.38 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price.
View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts.
How have IMCR shares performed in 2023?: Immunocore's stock was trading at $57.07 at the beginning of the year. Since then, IMCR shares have decreased by 8.8% and is now trading at $52.04.
View the best growth stocks for 2023 here.
When is Immunocore's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our IMCR earnings forecast.
How were Immunocore's earnings last quarter?: Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. The company earned $60.70 million during the quarter, compared to analyst estimates of $59.39 million. Immunocore had a negative net margin of 27.72% and a negative trailing twelve-month return on equity of 17.97%.
What ETFs hold Immunocore's stock?: ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP) and Range Cancer Therapeutics ETF (CNCR).BlackRock Future Health ETF (BMED).

When did Immunocore IPO?: (IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.
What is Immunocore's stock symbol?: Immunocore trades on the NASDAQ under the ticker symbol "IMCR."
Who are Immunocore's major shareholders?: Immunocore's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (6.30%), BlackRock Inc. (1.65%), Holocene Advisors LP (1.44%), Fiera Capital Corp (1.08%), Principal Financial Group Inc. (1.01%) and Braidwell LP (0.97%).
How do I buy shares of Immunocore?: Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immunocore's stock price today?: One share of IMCR stock can currently be purchased for approximately $52.04.
How much money does Immunocore make?: Immunocore (NASDAQ:IMCR) has a market capitalization of $2.55 billion and generates $173.59 million in revenue each year. The company earns $-50,990,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.
How many employees does Immunocore have?: The company employs 408 workers across the globe.
How can I contact Immunocore?: Immunocore's mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The official website for the company is www.immunocore.com. The company can be reached via phone at 44-12-3543-8600 or via email at ir@immunocore.com.

This page (NASDAQ:IMCR) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial